Give Feedback
Showing 63 results
  • NEW
    PEAK Matrix®

    July 16, 2025
    In recent years, life sciences enterprises have reprioritized and overhauled their R&D investments. They now focus on streamlining their pipelines and shifting toward new and large molecules. This transformation has compelled aggressive cost containment initiatives, prompting organizations to seek innovative commercialization strategies for their drugs and devices. Additionally, the growing focus on patient-centricity and customer experience has accelerated outsourcing to specialized providers. Providers are essential in this transformation. They offer expertise in generative AI, advanced analytics, and AI/ML, to streamline workflows and maximize efficiency. In response to market needs, they have expanded their portfolios to offer comprehensive, end-to-end solutions supporting pre-launch and post-launch commercialization activities. In this report, we assess 30 providers featured on the Life Sciences AI and Analytics Commercial Services PEAK Matrix® Report. Each provider profile highlights the service focus, key IP/solutions, domain-specific investments, and case studies.
  • Viewpoint

    June 12, 2025
    Life sciences enterprises are increasingly turning to Real-world Evidence (RWE) as an essential input for decision-making across the product life cycle – from early-stage R&D to post-market access and safety. RWE offers validated insights into treatment effectiveness, patient outcomes, and safety, but fragmented data sources, inconsistent quality, and evolving compliance expectations often challenge its generation. With the rising volume and diversity of Real-world Data (RWD), traditional analytics approaches are no longer sufficient. AI, including technologies such as NLP, machine learning, and generative models, is redefining how RWE is produced and operationalized. AI is accelerating data curation, enabling predictive analytics, and delivering regulatory-grade evidence at scale. This Viewpoint outlines how AI is transforming the RWE landscape across six domains: drug discovery, clinical trials, manufacturing, commercialization, pharmacovigilance, and regulatory affairs. It also explores emerging models such as insights-as-a-service and autonomous evidence networks, which offer scalable, modular engagement approaches for AI-powered RWE. The report provides practical recommendations for both enterprises and providers, covering capability investments, infrastructure modernization, governance models, and partnership strategies. It aims to help stakeholders reimagine their data-to-evidence journeys and build future-ready ecosystems for continuous, AI-enabled insight generation. Scope Industry: life sciences Geography: global Contents In this report, we examine: RWE’s current landscape and growing importance in life sciences AI’s role in addressing foundational RWE challenges AI-enabled key RWD/RWE use cases across the product life cycle Emerging engagement models such as BPaaS, AaaS, and IaaS Future-forward models, including autonomous evidence networks and modular AI-enabled partnerships Strategic considerations to operationalize AI-powered RWE for enterprises and providers
  • Viewpoint

    June 03, 2025
    As life sciences enterprises navigate the clinical development’s growing complexity due to advanced therapies, increased data volumes, and the need for operational agility, outsourcing models are evolving in response. Sponsors now seek flexible, cost-efficient, and expertise-driven models to accelerate time-to-market and maintain regulatory compliance. This Viewpoint examines core characteristics, market shifts, and strategic implications of Full-service Outsourcing (FSO) and Functional Service Provider (FSP) models in clinical operations. Sponsors can benefit from tailored insights to assess and refine their clinical outsourcing strategy. The report explores the increasing adoption of hybrid models, the rising influence of AI and cloud-based infrastructures, and key decision-making factors, such as therapeutic complexity and trial geography. It highlights how enterprises can unlock greater control, scalability, and innovation in clinical trials by selecting the right outsourcing mix. It empowers decision-makers with strategic insights to navigate evolving outsourcing models, enabling them to enhance operational agility, optimize costs, and maintain greater oversight. Scope Industry: life sciences Geography: global Contents In this report, we examine FSO and FSP outsourcing models’ features and use cases Market trends influencing the shift in outsourcing approaches Key decision-making factors for selecting the right model Challenges in implementing and optimizing outsourcing strategies The growing relevance and advantages of hybrid models in clinical operations
  • Viewpoint

    June 02, 2025
    The pharmaceutical industry is significantly transforming, driven by escalating R&D costs, rising competition, and a rapidly evolving global regulatory landscape. In this dynamic environment, regulatory affairs have emerged from their traditional compliance-focused roles to become strategic business agility enablers. Enterprises are increasingly recognizing the potential of AI, generative AI, and agentic AI to reduce manual workloads, accelerate time-to-market, and improve the accuracy and consistency of regulatory submissions. This report provides comprehensive insights into AI adoption’s current state in regulatory affairs, highlighting key challenges, value drivers, and investment trends. It explores prioritized strategic and operational use cases across regulatory processes and outlines how enterprises can overcome adoption hurdles through robust governance frameworks. The report also examines specialized providers’ evolving role in this transformation. Through their domain expertise, technology capabilities, and scalable solutions, these providers help reduce risk, ensure compliance, and enable faster time-to-market. Industry Life Sciences BPS Geography Global Contents In this report, we examine: Regulatory affairs’ evolving role in life sciences Current and future AI investment trends across pharma enterprises Leading AI use cases in regulatory strategy and operations A governance framework to address AI adoption challenges The strategic role of regulatory affairs specialist providers in accelerating AI adoption Memberships Life Sciences Business Process Sourcing and Vendor Management
  • Viewpoint

    May 07, 2025
    Increasing trial complexity, growing data volumes, and the rise of decentralized and real-world data sources are fundamentally transforming the clinical trial landscape. Traditional Clinical Data Management (CDM) processes are largely manual and rely on siloed data systems, making them inefficient and error-prone. In response, AI is emerging as an essential force in reshaping CDM. This Viewpoint analyzes the transformative roles of AI, generative AI and agentic AI, in modernizing CDM operations. It details how AI is enabling intelligent automation across the trial lifecycle, from protocol design and CRF setup to real-time data validation, anomaly detection, and regulatory documentation. Agentic AI is further pushing boundaries by enabling adaptive, autonomous decision-making with minimal human intervention. These capabilities not only reduce cycle times and improve data quality but also fundamentally shift how clinical teams manage, interact with, and derive insights from data. The report also offers a landscape view of AI-powered solutions across provider types, including global CROs, specialist CDM firms, and IT/BPO players. It outlines key cases, priority capabilities, and practical considerations for life sciences enterprises looking to integrate AI into their CDM strategies. Industry Life Sciences BPS Geography Global Contents In this report, we examine: The limitations of traditional CDM models in an increasingly complex data environment The role of AI, generative AI, and agentic AI in transforming CDM operations Key use cases across the CDM value chain The provider landscape, including differentiated value propositions across CROs, IT/BPO firms, and niche players Future outlook on multi-agent collaboration, autonomous compliance, and intelligent patient engagement through agentic AI Strategic considerations for evaluating and implementing AI-powered CDM solutions Memberships Clinical Development Technology Life Sciences Business Process Sourcing and Vendor Management

  • April 09, 2025
    In today’s dynamic talent market, organizations must actively monitor key roles and skills, both in-demand and emerging, to enable strategic workforce planning. Higher demand may indicate more significant competition for talent or a higher risk of attrition, making it vital to analyze talent demand trends to anticipate external competition and identify leading industries for talent acquisition. Everest Group’s half-yearly report offers insights into monthly IT services talent demand trends across India, highlighting top industries, roles, and skills based on H2 2024 demand. Leveraging data from our Talent Genius™ tool, this report comprehensively analyzes the current talent market, empowering organizations to stay competitive, plan for future workforce needs, and make informed talent acquisition decisions. Scope Industry: IT services Geography: India Contents In this report, we analyze talent demand trends in India's IT services sector on a national scale. Additionally, we provide detailed profiles of 15 major Tier-1 and Tier-2 cities, offering insights into talent demand trends, top industries, key roles, and essential skills in each location.
  • PEAK Matrix®

    April 03, 2025
    Pharmacovigilance (PV) has evolved into a strategic imperative, driven by intensified regulatory scrutiny and an increasing focus on patient safety. Pharmaceutical companies now face a rapidly evolving landscape characterized by rising adverse event volumes, fragmented real-world data sources, and increasingly complex global regulatory frameworks. Regional variations in drug safety reporting requirements further compound compliance challenges across diverse markets. At the same time, the demand for timely and accurate reporting has intensified, particularly as next-generation technologies introduce operational efficiencies while simultaneously raising regulatory concerns regarding the ethical and compliance implications of generative AI in PV. To navigate these complexities, external providers have become indispensable partners, offering deep PV expertise and adaptable support models. These providers bring proven drug safety process frameworks, highly trained PV professionals, and localized regulatory expertise, including qualified persons for PV, ensuring seamless compliance across global markets. Recognizing the need for enhanced efficiency, providers are investing in AI, automation, and advanced analytics to optimize case processing, adverse event management, and signal detection, all while reducing costs and improving operational scalability. In this report, we assess 29 PV operations providers featured on the Pharmacovigilance (PV) Operations PEAK Matrix®. Each provider profile provides a holistic picture of its service focus, solution offerings, and domain investments. The assessment is based on Everest Group’s annual RFI process for calendar year 2024, interactions with leading PV providers, client reference checks, and an ongoing analysis of the PV operations market. Scope Industry: life sciences Geography: global The assessment is based on Everest Group’s annual RFI process for calendar year 2024, interactions with leading PV providers, client reference checks, and ongoing analysis of the PV market Contents This report analyzes 29 providers in detail and includes: Their relative positioning on Everest Group’s Pre-approval Pharmacovigilance (PV) Operations PEAK Matrix® Their relative positioning on Everest Group’s Post-approval Pharmacovigilance (PV) Operations PEAK Matrix® A comparison of their capabilities and market shares Their strengths and limitations
  • Viewpoint

    Jan. 29, 2025
    This breaking viewpoint provides Everest Group’s view on how AI infusion – integrating AI into existing enterprise workflows – will outpace full AI replacement in key industries. It explores AI's role in financial services, healthcare, and regulatory compliance, where real-time fraud detection, anomaly identification, and instant diagnostics are driving transformation. The viewpoint highlights the advantages of embedding AI within current systems to enhance efficiency, reduce latency, and optimize decision-making. It provides insights into market trends, enterprise adoption strategies, and the evolving regulatory landscape, helping businesses navigate AI-driven innovation while maintaining operational continuity. Membership(s) Available to all membership areas
  • Thematic Report

    Jan. 24, 2025
    Generative AI can potentially revolutionize the life sciences industry, driving innovation across key areas of the value chain. By streamlining drug discovery, optimizing clinical trials, and enhancing decision-making, it can significantly reduce the time and cost required to bring new medicines to market, setting a new benchmark for industry efficiency and innovation. However, adopting generative AI presents challenges including concerns about data privacy, model accuracy, training resource demands, and ethical implications. As providers work toward addressing these challenges and generative AI becomes a key industry innovation driver, the focus is slowly moving beyond experimental pilot projects to full-scale implementations. This report examines generative AI’s value promise across the life sciences value chain, its market adoption within the industry, and the capabilities of 15 leading providers driving this innovation from pilots to scaled deployment. Scope Industry: life sciences Geography: global The assessment is based on Everest Group’s annual RFI process for the calendar year 2024, interactions with leading life sciences providers, client references, and Everest Group’s ongoing analysis of the life sciences market Contents In this report, we examine Generative AI’s value promise across different segments of the life sciences value chain Its market adoption in the life sciences industry 15 leading providers’ profiles Membership(s) Life Sciences Business Process Life Sciences Information Technology Sourcing and Vendor Management
  • State of the Market

    Dec. 27, 2024
    The impact sourcing ecosystem is rapidly expanding due to the growing interest in sustainable and socially responsible business practices. Enterprises and providers are increasingly incorporating diverse and underserved talent into their operations due to cost efficiency, access to specialized talent, and alignment with ESG and SDG objectives. Traditional providers dominate hiring volumes, while specialists see steady growth in revenue and headcount as they refine talent initiatives and partner with NGOs and educational institutions. Buyers recognize the dual value of cost benefits and corporate citizenship, advocating for more robust reporting and impact sourcing policies’ disclosure. In response, providers are investing in enhanced training programs, certifications, and technology upskilling, enabling impact workers to transition to more complex, higher-value roles. Despite generative AI’s disruptive potential concerns, agentic AI emerges as a promising tool to empower the impact workforce. Key market trends include the CXM industry’s increasing contribution to impact sourcing revenue, growing adoption of impact workers in MEA and APAC regions, and alignment with regulatory frameworks promoting fair labor practices. Governments support impact sourcing through incentives and regulations, while providers adopt inclusive hiring strategies and offer tailored employee support to complement workforce diversity and drive social impact. In this report, we explore macroeconomic drivers, buyer feedback, and generative AI’s influence on the impact sourcing space. Africa stands poised to lead the global impact sourcing growth, showing this approach’s transformative potential in fostering a purpose-driven and sustainable business landscape. The report aims to enable enterprises and providers to incorporate impact sourcing and other inclusive talent management strategies in their organizations. Scope Broad industry with a focus on impact sourcing talent strategy Geography: global Impact sourcing programs of both impact sourcing specialists and traditional service providers This report is based on primary and secondary data collection, conversations with market participants (buyers, outsourcing service providers, and impact sourcing specialists), and fact-based research Contents In this report, we analyze: The concept of impact sourcing and the comprehensive impact sourcing market landscape, including market size, trends, and talent portfolio Impact sourcing’s talent management practices across the hire-to-retire cycle Buyers’ take on impact sourcing Impact sourcing engagement case studies Technology’s role on the impact sourcing market and the future of impact sourcing programs Memberships This Market Report is available to All Memberships